Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

37.65 -1.46 (-3.73%)

Streaming Delayed Price Updated: 3:18 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

28 29 Next >

Why Viking Therapeutics Tumbled by More Than 10% This Week ↗

December 20, 2024

Via The Motley Fool

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up ↗

December 20, 2024

Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.

Via The Motley Fool

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗

December 20, 2024

Micron, Vertex, Novo Nordisk and Nike were notable losers on news.

Via Investor's Business Daily

Topics Economy

Looking Into Viking Therapeutics's Recent Short Interest ↗

December 20, 2024

Via Benzinga

Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗

December 20, 2024

Eli Lilly and Viking Therapeutics jumped on Novo's setback.

Via Investor's Business Daily

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

December 16, 2024

Via Benzinga

How Is The Market Feeling About Viking Therapeutics? ↗

November 22, 2024

Via Benzinga

From Powell To Profits: Strategic Stock Picks Amid Market Uncertainty ↗

December 19, 2024

Yesterday's market movement aligned perfectly with expectations, as the FOMC meeting drove significant volatility.

Via Talk Markets

Topics Stocks / Equities

What's Going On With Viking Therapeutics Stock On Wednesday? ↗

December 18, 2024

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 18, 2024

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

9 Health Care Stocks With Whale Alerts In Today's Session ↗

December 16, 2024

Via Benzinga

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗

December 16, 2024

Via The Motley Fool

2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗

December 15, 2024

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 10, 2024

Via Benzinga

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

December 10, 2024

Via The Motley Fool

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

December 05, 2024

Via The Motley Fool

After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now? ↗

December 03, 2024

Via The Motley Fool

2 Disruptive Growth Stocks With Room to Run ↗

December 03, 2024

Via The Motley Fool

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 02, 2024

Via Benzinga

Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum ↗

November 29, 2024

Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk.

Via Benzinga

Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow ↗

November 28, 2024

Via The Motley Fool

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs ↗

November 26, 2024

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Via Benzinga

Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗

November 25, 2024

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 23, 2024

Via The Motley Fool

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs ↗

November 20, 2024

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.

Via Benzinga

Money In Motion: Top Picks To Power Your Portfolio Today ↗

November 20, 2024

Top stocks set to dominate the market today.

Via Talk Markets

3 Things You Need to Know if You Buy Viking Therapeutics Today ↗

November 18, 2024

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

All News about Viking Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today